Recently, Ronapreve, a product of Roche Pharmaceuticals, was approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of mild to moderate COVID-19 patients by intravenous infusion.
The CDE issued five documents including the Technical Guidelines for the Research and Development of Prophylactic Vaccines against COVID-19 (Trial) on Aug. 14.